NASDAQ · BDSX
Healthcare · Medical - Diagnostics & Research
$21.49
Up+$0.44 (+2.09%)
Updated Nov 5, 2026, 3:43 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BDSX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
BDSX closed at $21.49 after 21 trading sessions, down 18.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $21.56 | $22.23 | $20.42 | $21.49 | 148.17K |
| Nov 3, 2026 | $21.80 | $22.89 | $20.74 | $21.05 | 38.79K |
| Nov 2, 2026 | $23.24 | $23.31 | $21.37 | $21.78 | 75.63K |
| Oct 30, 2026 | $25.06 | $25.06 | $22.695 | $23.255 | 67.25K |
| Oct 29, 2026 | $22.94 | $24.87 | $22.94 | $24.72 | 70.24K |
| Oct 28, 2026 | $21.87 | $22.98 | $21.27 | $22.86 | 101.35K |
| Oct 27, 2026 | $21.41 | $22.43 | $20.11 | $21.95 | 141.67K |
| Oct 26, 2026 | $21.54 | $22.36 | $21.02 | $21.26 | 60.94K |
| Oct 23, 2026 | $23.66 | $23.70 | $21.11 | $21.18 | 139.72K |
| Oct 22, 2026 | $23.76 | $24.99 | $23.3831 | $23.94 | 138.75K |
| Oct 21, 2026 | $24.07 | $24.55 | $23.66 | $23.93 | 54.21K |
| Oct 20, 2026 | $23.50 | $24.92 | $23.50 | $23.87 | 49.36K |
| Oct 19, 2026 | $23.68 | $25.24 | $23.04 | $23.40 | 55.41K |
| Oct 16, 2026 | $24.79 | $24.79 | $22.60 | $23.66 | 79.58K |
| Oct 15, 2026 | $23.92 | $24.77 | $23.84 | $24.71 | 35.21K |
| Oct 14, 2026 | $24.92 | $25.075 | $23.65 | $23.99 | 80.93K |
| Oct 13, 2026 | $25.79 | $25.79 | $24.80 | $25.00 | 53.32K |
| Oct 12, 2026 | $26.02 | $26.62 | $25.1865 | $25.70 | 40.97K |
| Oct 9, 2026 | $25.68 | $26.64 | $25.63 | $26.02 | 46.73K |
| Oct 8, 2026 | $26.24 | $26.505 | $25.10 | $25.63 | 95.95K |
| Oct 7, 2026 | $27.50 | $27.7807 | $26.0701 | $26.42 | 57.57K |
The latest Smart Investors Daily articles mentioning BDSX.
Company
Market Activity
Research & News
BDSX research
Company profile and research snapshot.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 25, 2026 | Roth Capital | Buy | — |
| Jun 18, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Oct 28, 2026
Labcorp (LH) delivered earnings and revenue surprises of +2.80% and +1.13%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 22, 2026
LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this
Yahoo · Oct 19, 2026
New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practicesLOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ: BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, “Building a Lung Nodule Program: From Detection to Diagnosis.” This groundbreaking framework descr
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDSX.
